IRIS

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。这项研究将确定吡格列酮是否将降低非糖尿病患者中风和心肌梗死的总体风险。目前，吡格列酮被批准用于治疗II型糖尿病。根据方案，年龄在44岁以上、最近有过缺血性中风的患者，如果他们有胰岛素抵抗，将被纳入研究范围。符合条件的患者将接受一项双盲研究，服用安慰剂或吡格列酮，总共为期三年。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study will determine if pioglitazone, currently approved for the treatment of type ii diabetes by reducing resistance, will reduce the overall risk for stroke and myocardial infarction in non-diabetic patients. Patients over the age of 44 years, who have had a recent ischemic stroke, will be enrolled if they have insulin resistance as tested per protocol. Patients who qualify will be on a doulbe blind study getting either placebo or pioglitazone for a total period of three years on the drug